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High-affinity SH2-targeted ligands
The Src homology 2 (SH2) domain plays a key role in the recognition of specific protein
sequences that contain a phosphotyrosine residue. Attempts to design agents that bind to the
SH2 domain has been driven by a desire to interrupt signalling pathways that are known to be
responsible for various diseases. Although the affinity of peptides for the SH2 domain lies in
the 200-800 nM range, any non-peptidic ligands are generally one to three orders of
magnitude less active.
A recent publication describes the parallel solid-phase synthesis of peptide/non-peptide
conjugates that have high affinity for the SH2 domains of Lck and Fyn (T.R. Lee and D.S.
Lawrence, J. Med. Chem., 42, (1999), 784-787). Using the Fmoc-protection protocol, a
phosphotyrosine containing peptide attached to the solid-phase through a disulphide linker
was derivatised by a range of carboxylic acids to generate 900 analogues. Cleavage of the
products allowed screening of their ability to bind to SH2 domains using an enzyme-linked
immunosorbent assay (ELISA). Although the majority of compounds failed to display any
affinity in the ELISA assay, several compounds including the coumarin derivative (1) and the
sulfonated compound (2) are among the most potent SH2-targeted agents identified.
YEEI-HN(CH2)2SH
PO3O
O OOH
2-
2-
YEEI-HN(CH2)2SH
PO3O
HO3S
COOH
(1) (2)
These two key compounds also demonstrated an unprecedented ability to discriminate
between the SH2 domains of two members of the Src family of protein kinases.
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Estrogen-receptor ligands
Estrogen pharmaceuticals based on both natural and synthetic substances have an important
role as agents for the control of fertility, hormone-responsive breast cancer and for
menopausal hormone replacement. Most synthetic estrogens retain a phenolic function, but
there are a considerable range of other synthetic types including both cyclic and acyclic
systems. A key goal of medicinal chemistry has been to obtain agents that have high levels of
tissue selectivity. The latest chapter in this process is the design of novel estrogen receptor
ligand templates that could be synthesised by simple condensation reactions typical of those
used in combinatorial chemistry (B.E. Fink et al., Chem. Biol., (1999), 6, 205-219).
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Many estrogen receptor ligands display a central core structure containing peripheral
structural elements and in this paper a number of 1,2- and 1,3-azole heterocycles (imidazole,
thiazole, oxazole and pyrazoles) were prepared and screened as receptor ligands. The binding
values, obtained from a competitive radiometric binding assay using tritiated estradiol,
demonstrated that of all these systems, pyrazoles had the highest binding affinity. In particular
the compounds (3) and (4) had high levels of binding and furthermore showed close
conformational relationships to the non-steroidal ligand raloxifene. The solid-phase synthesis
of related pyrazole libraries is underway in the search for more potent and selective estrogen
receptor ligands.
--------------------------------------------------------------------------------------------------------------
Thymidylate synthase inhibitors
Thymidylate synthase (TS) catalyses the final step in the biochemical pathway leading to
thymidylate and has been nominated as a target for the discovery of anticancer and
antimicrobial drugs. The x-ray structure of TS from Lactobacillus casei (LcTS) has been
derived and was the starting point for the design of novel library derived inhibitors (D. Tondi
et al., Chem. Biol., (1999), 6, 319-331). 153,516 compounds from the available chemicals
directory were screened against the x-ray structure using the molecular-docking programme
DOCK, and five high-ranking compounds were selected for screening. Of these, dansyltyosine
was selected for solid-phase synthesis of 33 analogues.
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One analogue discovered, didansyltyrosine (6), has an Ki value of 1.3 µM, demonstrating that
combinatorial chemistry and parallel synthesis techniques are complementary to structure-
based methods for the discovery of novel enzyme inhibitors that have no obvious similarity to
the enzyme substrate.
